Table 1 Demographic, clinicopathologic characteristics and concentration of urinary proteins in the study cohort
From: IL-8 as a urinary biomarker for the detection of bladder cancer
Non-cancer (%) | Cancer (%) | |
|---|---|---|
N=63 | N=64 | |
Median Age (range, y) | 60 (30-81) | 69.5 (22-90) |
Male : Female ratio | 55 : 8 | 55 : 9 |
Race | ||
White | 41 (65) | 58(91) |
African American | 8 (13) | 0(0) |
Other | 14 (22) | 6 (9) |
Tobacco use | 25 (40) | 54 (84) |
Gross hematuria | 0 (0) | 47 (73) |
Suspicious/positive cytology | 1 (2) | 18 (28) |
Median follow-up (months) | 11.5 | 12.0 |
Clinical stage | ||
Tis^ | n/a | 6(9) |
Ta | n/a | 15(23) |
T1 | n/a | 9 (14) |
T2 | n/a | 31(48) |
T3 | n/a | 4 (6) |
T4 | n/a | 2 (3) |
N+ ~ | n/a | 3 (5) |
Grade | ||
Low | n/a | 9(14) |
High | n/a | 55(86) |
Urinary Proteins | Median (range) | Median (range) |
IL-8 (pg/ml) | 0(0 - 134.33) | 128.43 (0 - 17140.2) |
MMP–9 (ng/ml) | 0 (0 – 14.25) | 0.95 (0 – 1002.6) |
Syndecan (ng/ml) | 40.67(0 - 199.55) | 31.81(0 - 335.18) |
BTA-Trak (U/ml) | 13.13(0.5 - 36.87) | 179.33 (0 - 24865.4) |
Hemoglobin (ng/ml) | 0(0 - 125.92) | 8.73 (0 - 130367.5) |
Mean + SD | Mean + SD | |
IL-8 (pg/ml) | 05.02 ± 20.99 | 1335.07 ±3495.26 |
MMP–9 (ng/ml) | 0.35 ±1.83 | 46.76 ±142.16 |
Syndecan (ng/ml) | 49.10 ± 42.09 | 55.04 ± 74.88 |
BTA-Trak (U/ml) | 14.66 ± 8.05 | 1630.5 ± 3954.5 |
Hemoglobin (ng/ml) | 2.63±15.97 | 4451.3±22814.4 |